Enanta Pharma (NASDAQ: ENTA) announced data from AbbVie’s SURVEYOR studies of its investigational treatment regimen, consisting of ABT-493, an NS3/4A ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE